Royalty Pharma (RPRX) Debt to Equity (2019 - 2025)
Royalty Pharma (RPRX) has disclosed Debt to Equity for 7 consecutive years, with $0.92 as the latest value for Q4 2025.
- Quarterly Debt to Equity rose 25.18% to $0.92 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $0.92 through Dec 2025, up 25.18% year-over-year, with the annual reading at $0.92 for FY2025, 25.18% up from the prior year.
- Debt to Equity hit $0.92 in Q4 2025 for Royalty Pharma, down from $0.93 in the prior quarter.
- In the past five years, Debt to Equity ranged from a high of $0.93 in Q3 2025 to a low of $0.57 in Q2 2021.
- Historically, Debt to Equity has averaged $0.72 across 5 years, with a median of $0.71 in 2022.
- Biggest five-year swings in Debt to Equity: fell 18.56% in 2023 and later grew 25.39% in 2025.
- Year by year, Debt to Equity stood at $0.7 in 2021, then grew by 6.28% to $0.75 in 2022, then dropped by 18.56% to $0.61 in 2023, then rose by 20.98% to $0.74 in 2024, then grew by 25.18% to $0.92 in 2025.
- Business Quant data shows Debt to Equity for RPRX at $0.92 in Q4 2025, $0.93 in Q3 2025, and $0.84 in Q2 2025.